CHARLOTTE, NC--(MARKET WIRE)--Aug 1, 2006 -- BurnsAdler Pharmaceuticals, Inc. announced today that it has entered into an agreement with Innocoll, Inc.'s subsidiary, Innocoll Pharmaceuticals Ltd., to license the company’s lead product, Gentamicin Surgical Implant, in Mexico, Chile, Colombia, Argentina and for select Caribbean islands. Marketed in Mexico under the tradename Garacoll®, the product is a lyophilized collagen sponge impregnated with the aminoglycoside antibiotic gentamicin and approved for the treatment and prevention of post-surgical infection and is sold in over 50 countries in Europe, North America, Africa and the Middle East.
Bryan Somerville, Executive Vice President of BurnsAdler, remarked, “We are very pleased to enter into this long-term relationship with Innocoll and to have the opportunity to bring Innocoll’s Gentamicin Surgical Implant to new markets where more patients can benefit from this exciting product. Innocoll has a long history of manufacturing this product and has done remarkable work in expanding sales since they acquired the worldwide rights in 2005. We are convinced that new attention to marketing Garacoll®, combined with the exciting results from recent clinical studies and a new product configuration, will rejuvenate the product in Mexico and provide for a successful launch in the other countries as well.”
Denise Carter, Corporate Vice President and President of Innocoll Pharmaceuticals, Inc., emphasized the importance of the alliance with BurnsAdler. “BurnsAdler is an experienced strategic partner in Central and South America, and we are delighted to announce this multi-country partnership in this territory. We look forward to growing the existing business in Mexico, where the product is already on the market, and expanding the product’s reach into new countries.”
BurnsAdler is a specialty pharmaceutical company that in-licenses and promotes products in Europe, South America, Mexico, Canada, Puerto Rico and the Caribbean. BurnsAdler’s portfolio currently includes products targeted for the gastroenterology, cardiovascular, orthopedic, oncology, CNS and critical care markets.
Innocoll, Inc. is a privately owned specialty pharmaceutical company engaged in the research, development, commercial supply, and marketing of advanced, differentiated products using proprietary, innovative collagen-based technology platforms (CollaRx(TM) and LiquiColl®) for the targeted delivery of a wide variety of medicines. Innocoll Technologies is the company’s drug delivery division dedicated to the research and development of products based on CollaRx and LiquiColl. The CollaRx technology has been fully scaled up and commercialized. The company’s lead product, Gentamicin Surgical Implant, is indicated for the treatment and prevention of hard and soft tissue infection post-surgery by the company’s sales and marketing division, Innocoll Pharmaceuticals.
For additional information about this news release contact Bryan Somerville at +1.704.552.8410 Ext. 223. For additional information about BurnsAdler, please refer to the company’s website at www.burnsadler.com.
Contact:
BurnsAdler Contact: Bryan Somerville Executive Vice President +1.704.552.8410 (phone) Ext. 223 +1.704.552.8411 (fax) Email Contact
Source: BurnsAdler Pharmaceuticals, Inc.
